Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747572 · ClinicalTrials.gov registry record
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
A clinical trial of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- 401
- Enrollment target
- 20
- Study locations
NCT06747572: Active study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
NCT06747572 is a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 401 participants, below the 712-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06747572, a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- 401 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
Conditions Studied
Study Locations (20)
California
- Kaiser Permanente - Los Angeles Medical Center - Los Angeles
- UCLA Division of Nephrology - Los Angeles
- Helen Diller Medical Center at Parnassus Heights - San Francisco
Alabama
- Alabama Kidney Research - Alabaster
- University of Alabama at Birmingham- Nephrology Research Clinic - Birmingham
Connecticut
- Nephrology & Hypertension Associates, PC - Middlebury
- Yale Nephrology Clinical Research Clinic - New Haven
Florida
- Nature Coast Clinical Research - Inverness - Inverness
- Mayo Clinic - Jacksonville - Jacksonville
Georgia
- Emory School of Medicine - Renal Division - Atlanta
- Renal Associates, LLC - Columbus
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Nephrology - Boston
Minnesota
- University of Minnesota -Health Clinical Research Unit - Minneapolis
- Mayo Clinic - Rochester - Rochester
Illinois
- UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT06747572 still lists
NCT06747572 is an observational study that tracks outcomes without assigning an intervention. The registered 401 participants enrollment target is mid-sized for trials with a published cap, below the 712-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 0 interventions.
NCT06747572 names 20 study sites across 12 states, led by California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06747572 about?
NCT06747572 is a clinical study titled "Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease". The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
What is the current status of trial NCT06747572?
This trial is currently active not recruiting. The enrollment target is 401 participants. The study started on 2024-12-19. Estimated completion is 2026-12-31.
What conditions does trial NCT06747572 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Who is sponsoring clinical trial NCT06747572?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747572 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
RECRUITING · NA
-
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
RECRUITING · Phase 2
-
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI